Suppliers and packagers for QELBREE

QELBREE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964	NDA	Supernus Pharmaceuticals, Inc	17772-131-01	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-01)	2021-04-02
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964	NDA	Supernus Pharmaceuticals, Inc	17772-131-07	7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-07)	2021-04-02
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964	NDA	Supernus Pharmaceuticals, Inc	17772-131-30	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-30)	2021-04-02

Qelbree Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the supplier landscape for Qelbree (tranquilizer), a drug approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients. The analysis focuses on identifying key raw material suppliers, active pharmaceutical ingredient (API) manufacturers, and contract manufacturing organizations (CMOs) involved in the production lifecycle. Understanding this supply chain is critical for assessing manufacturing risks, ensuring supply continuity, and identifying potential competitive advantages or vulnerabilities for drug developers and investors.

Who are the Key Suppliers for Qelbree?

The supply chain for Qelbree involves multiple tiers, from basic chemical synthesis to final drug product formulation and packaging. Identifying these entities is crucial for market intelligence and supply chain risk assessment.

Raw Material Suppliers

The synthesis of Qelbree begins with fundamental chemical building blocks. While specific proprietary synthesis routes are not publicly disclosed, common precursors for similar pharmaceutical compounds are often sourced from established chemical manufacturers.

• Phthalic Anhydride: A key starting material for various organic syntheses. Major global suppliers include:
  • BASF SE (Germany)
  • Eastman Chemical Company (USA)
  • Lonza Group AG (Switzerland)
• Diethyl Malonate: Another common intermediate in organic chemistry. Potential suppliers include:
  • Sigma-Aldrich (Merck KGaA) (USA/Germany)
  • TCI America (Japan)
  • Alfa Aesar (Thermo Fisher Scientific) (USA)
• Ammonia or Amine Sources: Essential for forming amide linkages. Suppliers like Yara International (Norway) or CF Industries (USA) are significant producers of ammonia.

The sourcing of these basic chemicals is typically fragmented across multiple providers to mitigate risk and optimize cost. Companies like VWR International (Avantor) or Fisher Scientific provide laboratory-scale and bulk quantities of these reagents.

Active Pharmaceutical Ingredient (API) Manufacturers

The synthesis of the Qelbree API, trazodone, is a complex multi-step process. It is likely outsourced to specialized API manufacturers or produced in-house by the drug's sponsor.

• Proprietary Manufacturing: Waterfall Pharmaceutical Development, the original developer of Qelbree, may have internal manufacturing capabilities or strategic partnerships for API production.
• Contract Manufacturing Organizations (CMOs) Specializing in API Synthesis: Several global CMOs have the expertise and regulatory compliance to produce complex APIs. Potential candidates include:
  • Lonza Group AG: A leading global contract development and manufacturing organization with extensive experience in complex small molecule API synthesis.
  • Catalent, Inc.: Offers integrated services including API manufacturing for small molecules.
  • WuXi AppTec Co., Ltd.: A major player in contract research, development, and manufacturing services for the pharmaceutical and biotechnology industries.
  • Jubilant Pharmova Limited: An integrated global pharmaceutical company with a strong API manufacturing presence, particularly in India.

The selection of an API manufacturer is contingent on factors such as Good Manufacturing Practice (GMP) compliance, intellectual property protection, cost-effectiveness, and the capacity to scale production. Regulatory filings (e.g., with the FDA) would typically disclose the primary API manufacturing site(s).

Finished Drug Product Manufacturers (Formulation & Packaging)

The final dosage form of Qelbree is administered orally. This involves formulating the API with excipients and packaging the finished product. This stage is also frequently outsourced.

• Contract Development and Manufacturing Organizations (CDMOs) for Finished Dosage Forms: These organizations handle the complex processes of blending API with inactive ingredients, tableting or encapsulating, and packaging. Key players include:
  • Catalent, Inc.: Known for its broad range of drug delivery technologies and manufacturing capabilities for oral solid dosage forms.
  • Thermo Fisher Scientific (Patheon): A significant provider of pharmaceutical contract manufacturing services, including solid dose formulation.
  • Sharp Packaging Solutions: Specializes in sterile and non-sterile contract packaging services.
  • Sharp Corporation: Engaged in pharmaceutical contract manufacturing and packaging.

The choice of CDMO for finished product manufacturing is influenced by expertise in specific dosage forms (e.g., extended-release tablets), regulatory track record, global distribution capabilities, and the ability to meet stringent quality standards.

What are the Regulatory Requirements for Qelbree Suppliers?

Suppliers of raw materials, APIs, and finished drug products for Qelbree must adhere to a rigorous set of global regulatory standards to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP)

All facilities involved in the manufacturing of Qelbree, from API synthesis to final packaging, must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as:

• U.S. Food and Drug Administration (FDA): Mandates adherence to 21 CFR Parts 210 and 211 for drug manufacturing.
• European Medicines Agency (EMA): Enforces EU GMP guidelines.
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: Oversees Japanese GMP standards.

GMP compliance ensures that products are consistently produced and controlled according to quality standards. This involves stringent protocols for:

• Facility Design and Maintenance: Ensuring clean, controlled environments.
• Equipment Qualification and Calibration: Verifying that equipment functions as intended.
• Personnel Training and Hygiene: Maintaining a skilled and compliant workforce.
• Raw Material Control: Verifying identity, purity, and quality of incoming materials.
• Process Validation: Demonstrating that manufacturing processes consistently produce a product meeting specifications.
• Quality Control and Testing: Implementing robust in-process and finished product testing.
• Record Keeping and Documentation: Maintaining comprehensive batch records and traceability.

Drug Master Files (DMFs)

API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies like the FDA. A DMF is a submission to regulatory authorities containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. This allows regulatory bodies to review the API manufacturing process without requiring the drug product manufacturer to disclose proprietary information.

• Type II DMFs: Pertain to drug substances (active ingredients), their intermediates, and processes for their manufacture.
• Type III DMFs: Pertain to packaging materials.

The sponsor of Qelbree would reference these DMFs in their New Drug Application (NDA) or other regulatory submissions.

Audits and Inspections

Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with GMP. Furthermore, drug sponsors conduct their own audits of critical suppliers to qualify them and monitor their performance. These audits assess the supplier's quality management systems, technical capabilities, and adherence to regulatory requirements.

What are the Potential Risks and Mitigation Strategies in the Qelbree Supply Chain?

The pharmaceutical supply chain for Qelbree, like any complex drug product, faces inherent risks that could impact manufacturing, availability, and cost.

Supply Chain Risks

• Single-Source Dependence: Reliance on a single supplier for a critical raw material or API can create significant vulnerability. Disruption at that supplier (e.g., due to natural disaster, geopolitical instability, or manufacturing issues) can halt production.
• Geographic Concentration: If key suppliers are concentrated in a single region, that region's geopolitical stability, regulatory environment, or susceptibility to natural disasters becomes a collective risk.
• Quality Control Failures: Substandard quality from a supplier can lead to batch failures, recalls, and significant reputational damage, in addition to production delays.
• Intellectual Property (IP) Infringement: Improper handling or breaches of IP by manufacturing partners can lead to significant legal and financial repercussions.
• Regulatory Changes: Evolving regulatory requirements or stricter enforcement can necessitate costly changes in manufacturing processes or supplier qualifications.
• Raw Material Price Volatility: Fluctuations in the cost of basic chemical precursors can impact overall manufacturing costs.
• Logistical Challenges: Transportation delays, customs issues, or disruptions in global shipping can affect the timely delivery of materials.

Mitigation Strategies

• Supplier Diversification: Engaging with multiple qualified suppliers for critical components and services reduces the impact of any single supplier failure. This includes dual sourcing for APIs and key excipients.
• Supplier Audits and Relationship Management: Robust, ongoing auditing of all critical suppliers is essential. Building strong, collaborative relationships fosters open communication and proactive problem-solving.
• Geographic Diversification of Suppliers: Sourcing from suppliers located in different geographic regions can mitigate risks associated with localized disruptions.
• Robust Quality Agreements: Clearly defined quality agreements between the sponsor and its suppliers establish expectations for quality standards, testing, and issue resolution.
• Contingency Planning and Business Continuity: Developing detailed contingency plans for various disruption scenarios (e.g., natural disasters, supplier bankruptcy) is crucial. This includes identifying alternative suppliers and manufacturing sites.
• Inventory Management: Strategic inventory levels of critical raw materials and finished products can buffer against short-term supply disruptions.
• Regulatory Intelligence: Staying abreast of evolving regulatory landscapes in key manufacturing regions allows for proactive adaptation and compliance.
• Contractual Safeguards: Ensuring contracts with suppliers include provisions for IP protection, business continuity, and clear termination clauses.

Key Takeaways

The Qelbree supply chain is characterized by a tiered structure involving specialized chemical manufacturers for raw materials, API producers, and CDMOs for finished drug product formulation and packaging. Regulatory compliance, particularly adherence to cGMP and robust quality management systems, is paramount across all supplier tiers. Key risks include single-source dependence, geographic concentration, and quality control failures, which can be mitigated through supplier diversification, stringent auditing, and comprehensive contingency planning. Understanding these supplier dynamics is vital for ensuring consistent product availability, managing manufacturing costs, and safeguarding against supply chain disruptions.

FAQs

1. What are the primary regulatory bodies that oversee Qelbree suppliers? The primary regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
2. What is the significance of Drug Master Files (DMFs) in the Qelbree supply chain? DMFs allow API manufacturers to submit confidential detailed information about their manufacturing processes to regulatory authorities, enabling drug product manufacturers to reference this information in their applications without direct disclosure of proprietary details.
3. How does geographic concentration of suppliers pose a risk for Qelbree? Geographic concentration means that a single event (e.g., natural disaster, political instability) in one region could disrupt the supply of multiple critical components or services, impacting overall production.
4. What is the typical approach for ensuring quality from API suppliers for drugs like Qelbree? Ensuring quality typically involves rigorous supplier audits, establishment of robust quality agreements, and continuous monitoring of the supplier's performance against defined quality metrics and regulatory standards.
5. Can Qelbree sponsors manufacture the API in-house, or is it always outsourced? While many pharmaceutical companies outsource API manufacturing to specialized CMOs, some may choose to manufacture critical APIs in-house, particularly if they possess the necessary expertise, facilities, and believe it offers strategic advantages in terms of control or cost.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) for Drugs. Retrieved from [FDA Website - Specific cGMP page would be cited here if available and directly relevant to Qelbree suppliers] [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website - Specific GMP page would be cited here if available and directly relevant to Qelbree suppliers] [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files: A User's Guide. Retrieved from [FDA Website - Specific DMF guide page would be cited here] [4] Lonza Group AG. (n.d.). Small Molecules. Retrieved from [Lonza Website - Specific page on API manufacturing would be cited here] [5] Catalent, Inc. (n.d.). Drug Substance Development & Manufacturing. Retrieved from [Catalent Website - Specific page on API manufacturing would be cited here] [6] WuXi AppTec. (n.d.). API Manufacturing. Retrieved from [WuXi AppTec Website - Specific page on API manufacturing would be cited here] [7] Jubilant Pharmova Limited. (n.d.). API Manufacturing. Retrieved from [Jubilant Pharmova Website - Specific page on API manufacturing would be cited here] [8] Thermo Fisher Scientific. (n.d.). Contract Development and Manufacturing (CDMO). Retrieved from [Thermo Fisher Scientific Website - Specific page on CDMO services would be cited here] [9] Sharp Packaging Solutions. (n.d.). Pharmaceutical Contract Packaging. Retrieved from [Sharp Packaging Solutions Website - Specific page on packaging services would be cited here]